Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments - Narrative (Details)

v3.20.2
Revenue Recognition and Contractual Adjustments - Narrative (Details)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
segment
Revenue from Contract with Customer [Abstract]    
Number of operating segments | segment   2
Increase in Pharma contract assets   $ 0.7
Pharma contract asset, increase (as a percent) 56.00% 56.00%
Increase in pharma contract liabilities   $ 1.6
Increase in pharma contract liabilities (as a percent)   57.00%
Pharma contract liability, revenue recognized $ 0.5 $ 2.1
Amortization of contract commissions $ 0.3 $ 0.6